Search Results 1031-1040 of 17874 for monoclonal antibody

1. A Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of RO7303509 In Participants With Systemic Sclerosis - Mayo Clinic

   monoclonal antibodies. - Immunization with a live/attenuated vaccine within ... study or within 3 months after the final dose. - Positive hepatitis C virus (HCV) ...

2. Mayo Clinic researchers find new hope for toughest myeloma through off-the-shelf immunotherapy

   ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...

3. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... monoclonal antibody (bevacizumab, ramucirumab, or aflibercept), and an anti-PD-1 monoclonal antibody (nivolumab or pembrolizumab) if tumor has deficient ...

4. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antibody-like drugs, cytokines, cell therapies, or radioimmunoconjugates: 4 weeks.

5. A Phase 1/2 Study To Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of HMB-001 In Glanzmann Thrombasthenia - Mayo Clinic

   Severe infection or inflammation at the time of Screening. 2. History of clinically significant hypersensitivity associated with monoclonal antibody

6. A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

   ... monoclonal antibody against LOXL2, in patients with IPF. Read More on PubMed. Additional contact information. Non-cancer trials contact form. Phone: 800-664 ...

7. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

   Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Managing flares and IBD symptoms. Crohn's and Colitis ...

8. A Study to Evaluate the Safety and Effectiveness of JBH492 in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma - Mayo Clinic

   ... monoclonal antibody administration. Any prior history of treatment with maytansine (DM1 or DM4)-based ADC. Known intolerance to a maytansinoid. Patients ...

9. A Study Of Long-acting Antibodies Alone And In Combinations For Moderate To Severe Ulcerative Colitis - Mayo Clinic

   This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary ...

10. A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) - Mayo Clinic

    antibody (TDB) antibody including non BCMA targeting TDB - Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC as anti-cancer therapy ...